Interleukin 1 (IL1) - Pipeline Review, H1 2018
Interleukin 1 (IL1) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Interleukin 1 (IL1) - Pipeline Review, H1 2018'; Interleukin 1 (IL1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.
Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.
The report 'Interleukin 1 (IL1) - Pipeline Review, H1 2018' outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 6, 1, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Cardiovascular, Immunology, Metabolic Disorders, Oncology, Dermatology, Musculoskeletal Disorders, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Central Nervous System and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Non-Small Cell Lung Cancer, Epidermolysis Bullosa, Inflammation, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Type 2 Diabetes, Acne Vulgaris, Atopic Dermatitis, Autoimmune Disorders, Bladder Cancer, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cervical Cancer, Colorectal Cancer, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Inflammatory Bowel Disease, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Skin Inflammation, Skin Ulcers, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Interleukin 1 (IL1) - Pipeline Review, H1 2018'; Interleukin 1 (IL1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.
Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity.
The report 'Interleukin 1 (IL1) - Pipeline Review, H1 2018' outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 6, 1, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Cardiovascular, Immunology, Metabolic Disorders, Oncology, Dermatology, Musculoskeletal Disorders, Ear Nose Throat Disorders, Gastrointestinal, Genetic Disorders, Central Nervous System and Genito Urinary System And Sex Hormones which include indications Gouty Arthritis (Gout), Non-Small Cell Lung Cancer, Epidermolysis Bullosa, Inflammation, Atherosclerosis, Behcet Disease, Familial Mediterranean Fever, Type 2 Diabetes, Acne Vulgaris, Atopic Dermatitis, Autoimmune Disorders, Bladder Cancer, Bullous Pemphigoid, Cancer Anorexia-Cachexia Syndrome, Cardiovascular Risk Factors, Cervical Cancer, Colorectal Cancer, Diabetes, Esophageal Cancer, Fallopian Tube Cancer, Hearing Disorders, Hidradenitis Suppurativa, Hypercholesterolemia, Inflammatory Bowel Disease, Kidney Fibrosis, Liver Fibrosis, Lymphoma, Metastatic Colorectal Cancer, Mevalonate Kinase Deficiency (Hyperimmunoglobulin D Syndrome (HIDS)), Muckle-Wells Syndrome, Myocardial Infarction, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pain, Pancreatic Cancer, Pericarditis, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Restenosis, Rheumatoid Arthritis, Rhinitis, Sarcoidosis, Skin Inflammation, Skin Ulcers, Systemic Idiopathic Juvenile Arthritis and Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (Familial Hibernian Fever).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
- The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Interleukin 1 (IL1) - Overview
Interleukin 1 (IL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
Apexigen Inc
Exicure Inc
Immune Response BioPharma Inc
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
Interleukin 1 (IL1) - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-2752 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMN-54 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilonacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-15008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suramin hexasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xilonix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 (IL1) - Dormant Products
Interleukin 1 (IL1) - Discontinued Products
Interleukin 1 (IL1) - Product Development Milestones
Featured News & Press Releases
Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology
Mar 12, 2018: Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes
Feb 26, 2018: TWi Biotechnology Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa
Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Jan 15, 2018: Castle Creek Pharmaceuticals Announces Data Validating First Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research
Jan 03, 2018: Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit
Dec 04, 2017: XBiotech Announces Publication of Phase II Data from Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology
Nov 14, 2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
Nov 13, 2017: Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Nov 13, 2017: Response after Single Treatment with Canakinumab Predicts Which Patients Will Benefit Most
Nov 03, 2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting
Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Interleukin 1 (IL1) - Overview
Interleukin 1 (IL1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
Apexigen Inc
Exicure Inc
Immune Response BioPharma Inc
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
Interleukin 1 (IL1) - Drug Profiles
AC-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LH-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mRNA-2752 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMN-54 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilonacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOBI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-15008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suramin hexasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Xilonix - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 (IL1) - Dormant Products
Interleukin 1 (IL1) - Discontinued Products
Interleukin 1 (IL1) - Product Development Milestones
Featured News & Press Releases
Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology
Mar 12, 2018: Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes
Feb 26, 2018: TWi Biotechnology Announced Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical trial of AC-203 for treatment of Inherited Epidermolysis Bullosa
Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
Jan 15, 2018: Castle Creek Pharmaceuticals Announces Data Validating First Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research
Jan 03, 2018: Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit
Dec 04, 2017: XBiotech Announces Publication of Phase II Data from Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology
Nov 14, 2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions
Nov 13, 2017: Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Nov 13, 2017: Response after Single Treatment with Canakinumab Predicts Which Patients Will Benefit Most
Nov 03, 2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
Nov 01, 2017: TWi Biotechnology Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting
Oct 27, 2017: Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Apexigen Inc, H1 2018
Pipeline by Exicure Inc, H1 2018
Pipeline by Immune Response BioPharma Inc, H1 2018
Pipeline by Moderna Therapeutics Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Omnitura Therapeutics Inc, H1 2018
Pipeline by Opsona Therapeutics Ltd, H1 2018
Pipeline by Optimum Therapeutics LLC, H1 2018
Pipeline by Peptinov SAS, H1 2018
Pipeline by R Pharm, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Pipeline by Spherium Biomed SL, H1 2018
Pipeline by Swedish Orphan Biovitrum AB, H1 2018
Pipeline by XBiotech Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Dormant Products, H1 2018 (Contd.4), H1 2018
Dormant Products, H1 2018 (Contd.5), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Apexigen Inc, H1 2018
Pipeline by Exicure Inc, H1 2018
Pipeline by Immune Response BioPharma Inc, H1 2018
Pipeline by Moderna Therapeutics Inc, H1 2018
Pipeline by Novartis AG, H1 2018
Pipeline by Omnitura Therapeutics Inc, H1 2018
Pipeline by Opsona Therapeutics Ltd, H1 2018
Pipeline by Optimum Therapeutics LLC, H1 2018
Pipeline by Peptinov SAS, H1 2018
Pipeline by R Pharm, H1 2018
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018
Pipeline by Spherium Biomed SL, H1 2018
Pipeline by Swedish Orphan Biovitrum AB, H1 2018
Pipeline by XBiotech Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Dormant Products, H1 2018 (Contd.3), H1 2018
Dormant Products, H1 2018 (Contd.4), H1 2018
Dormant Products, H1 2018 (Contd.5), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018 (Contd.2), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Apexigen Inc
Exicure Inc
Immune Response BioPharma Inc
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Apexigen Inc
Exicure Inc
Immune Response BioPharma Inc
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Optimum Therapeutics LLC
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
XBiotech Inc
